ReviewCancer science2010
Cellular context-dependent "colors" of transforming growth factor-beta signaling.
Review in Cancer science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 77 citations in OpenAlex.
- OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance.Molecular cancer research : MCR · 2026Article
- TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.Cancer science · 2026Article
- OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer.bioRxiv : the preprint server for biology · 2025Article
- Investigating the impact of SMAD2 and SMAD4 downregulation in colorectal cancer and their correlation with immune markers, prognosis, and drug resistance and sensitivity.Molecular biology reports · 2024Article
- Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- SET8 is a novel negative regulator of TGF-β signaling in a methylation-independent manner.Scientific reports · 2023Article
- TGFβ-2 haploinsufficiency causes early death in mice with Marfan syndrome.Matrix biology : journal of the International Society for Matrix Biology · 2023Article
- Molecular characterization and expression of TGFβRI and TGFβRII and its association with litter size in Tibetan sheep.Veterinary medicine and science · 2023Article
- Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression.Cancer metastasis reviews · 2022Review
- Identification of Prognostic Gene Biomarkers in Non-Small Cell Lung Cancer Progression by Integrated Bioinformatics Analysis.Biology · 2021Article
- Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development.Cell reports · 2020Article
- Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells.Medicines (Basel, Switzerland) · 2020Article
- Article
- Review
- miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.Breast cancer research and treatment · 2019Article
- PEG10 counteracts signaling pathways of TGF-β and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells.Journal of bone and mineral metabolism · 2019Article
- Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer.Current opinion in systems biology · 2018Review
- Molecular mechanisms underlying the antimetastatic activity of bufalin.Molecular and clinical oncology · 2018Review
- TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.Cold Spring Harbor perspectives in biology · 2017Review
- TMED10 Protein Interferes with Transforming Growth Factor (TGF)-β Signaling by Disrupting TGF-β Receptor Complex Formation.The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor (TGF)-beta signaling has interesting characteristics in the context of cancer. Although perturbations of TGF-beta signaling are strongly implicated in cancer progression, TGF-beta signaling has both tumor-suppressive and tumor-promoting effects. For example, TGF-beta inhibits cancer cell proliferation in some cellular contexts, but promotes it in others. Although several approaches to treating cancer have been considered using TGF-beta-based therapeutic strategies, the contradictory behaviors of TGF-beta have made these approaches complex. To put them to practical use, either the tumor-suppressive or tumor-promoting arm needs to be specifically manipulated. However, there is virtually no method to specifically regulate a certain cell response induced by TGF-beta. In this review, we first consider the basic machinery of TGF-beta signaling, and describe several cell responses induced by TGF-beta stimulation in specific contexts. Mechanisms by which TGF-beta can induce several responses in a cellular context-dependent fashion are discussed with established paradigms and models. We also address perspectives on the specific control of only a subset of numerous cell responses induced by TGF-beta stimulation. Such methods will aid specific regulation of either the tumor-suppressive or tumor-promoting arm of the TGF-beta pathway and in realization of TGF-beta-based treatment of malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.